The Role of the NLRP3 Inflammasome in Gout

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2011 Nov 19

PMID 22096368

Citations 107

Authors

Sarah R Kingsbury

Philip G Conaghan

Michael F McDermott

Affiliations

Soon will be listed here.

Abstract

Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint. Recent studies suggest that orchestration of the MSU-induced inflammatory response is dependent on the proinflammatory cytokine IL-1β, underlined by promising results in early IL-1 inhibitor trials in gout patients. This IL-1-dependent innate inflammatory phenotype, which is observed in a number of diseases in addition to gout, is now understood to rely on the formation of the macromolecular NLRP3 inflammasome complex in response to the MSU 'danger signal'. This review focuses on our current understanding of the NLRP3 inflammasome and its critical role in MSU-crystal induced inflammatory gout attacks. It also discusses the management of treatment-resistant acute and chronic tophaceous gout with IL-1 inhibitors; early clinical studies of rilonacept (IL-1 Trap), canakinumab (monoclonal anti-IL-1β antibody), and anakinra have all demonstrated treatment efficacy in such patients.

Citing Articles

NLRP3 inflammasomes pathway: a key target for Metformin.

Hosseini Y, Niknejad A, Sabbagh Kashani A, Gholami M, Roustaie M, Mohammadi M Inflammopharmacology. 2025; .

PMID: 40042723 DOI: 10.1007/s10787-025-01702-4.

Combining Colchicine and Antiplatelet Therapy to Tackle Atherothrombosis: A Paradigm in Transition?.

Giordano S, Camera M, Brambilla M, Sarto G, Spadafora L, Bernardi M Int J Mol Sci. 2025; 26(3).

PMID: 39940905 PMC: 11817323. DOI: 10.3390/ijms26031136.

A review on NLRP3 inflammasome modulation by animal venom proteins/peptides: mechanisms and therapeutic insights.

Balde A, Benjakul S, Nazeer R Inflammopharmacology. 2025; .

PMID: 39934538 DOI: 10.1007/s10787-025-01656-7.

The pathogenesis of gout.

Ahn E, So M J Rheum Dis. 2024; 32(1):8-16.

PMID: 39712248 PMC: 11659655. DOI: 10.4078/jrd.2024.0054.

A targeted proteomics screen reveals serum and synovial fluid proteomic signature in patients with gout.

Huang Z, Zhong X, Zhang Y, Li X, Liu M, Huang Y Front Immunol. 2024; 15:1468810.

PMID: 39611154 PMC: 11602490. DOI: 10.3389/fimmu.2024.1468810.

References

Meissner F, Molawi K, Zychlinsky A . Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol. 2008; 9(8):866-72. DOI: 10.1038/ni.1633. View

Jordan K, Cameron J, Snaith M, Zhang W, Doherty M, Seckl J . British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007; 46(8):1372-4. DOI: 10.1093/rheumatology/kem056a. View

Pelegrin P, Surprenant A . Pannexin-1 couples to maitotoxin- and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem. 2006; 282(4):2386-94. DOI: 10.1074/jbc.M610351200. View

Lamkanfi M, Denecker G, Kalai M, DHondt K, Meeus A, Declercq W . INCA, a novel human caspase recruitment domain protein that inhibits interleukin-1beta generation. J Biol Chem. 2004; 279(50):51729-38. DOI: 10.1074/jbc.M407891200. View

Masters S, Dunne A, Subramanian S, Hull R, Tannahill G, Sharp F . Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol. 2010; 11(10):897-904. PMC: 3103663. DOI: 10.1038/ni.1935. View

Kastbom A, Verma D, Eriksson P, Skogh T, Wingren G, Soderkvist P . Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology (Oxford). 2008; 47(4):415-7. DOI: 10.1093/rheumatology/kem372. View

Hornung V, Bauernfeind F, Halle A, Samstad E, Kono H, Rock K . Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9(8):847-56. PMC: 2834784. DOI: 10.1038/ni.1631. View

Hoffman H, Throne M, Amar N, Sebai M, Kivitz A, Kavanaugh A . Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 2008; 58(8):2443-52. DOI: 10.1002/art.23687. View

Kawai T, Akira S . Antiviral signaling through pattern recognition receptors. J Biochem. 2006; 141(2):137-45. DOI: 10.1093/jb/mvm032. View

10.

Lin Y, Lee H, Berg A, Lisanti M, Shapiro L, Scherer P . The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem. 2000; 275(32):24255-63. DOI: 10.1074/jbc.M002137200. View

11.

Franchi L, Kanneganti T, Dubyak G, Nunez G . Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem. 2007; 282(26):18810-8. DOI: 10.1074/jbc.M610762200. View

12.

Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris D . Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem. 2009; 285(9):6477-88. PMC: 2825443. DOI: 10.1074/jbc.M109.064907. View

13.

Hoffman H . Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther. 2009; 9(4):519-31. DOI: 10.1517/14712590902875518. View

14.

. Carl Wilhelm Scheele (1742-1786) Swedish apothecary. JAMA. 1970; 212(13):2258-9. View

15.

Fadok V, Bratton D, Konowal A, Freed P, Westcott J, Henson P . Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998; 101(4):890-8. PMC: 508637. DOI: 10.1172/JCI1112. View

16.

Scott A, Saleh M . The inflammatory caspases: guardians against infections and sepsis. Cell Death Differ. 2006; 14(1):23-31. DOI: 10.1038/sj.cdd.4402026. View

17.

Netea M, Nold-Petry C, Nold M, Joosten L, Opitz B, van der Meer J . Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2008; 113(10):2324-35. PMC: 2652374. DOI: 10.1182/blood-2008-03-146720. View

18.

Goldbach-Mansky R, Dailey N, Canna S, Gelabert A, Jones J, Rubin B . Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006; 355(6):581-92. PMC: 4178954. DOI: 10.1056/NEJMoa055137. View

19.

Cassel S, Eisenbarth S, Iyer S, Sadler J, Colegio O, Tephly L . The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A. 2008; 105(26):9035-40. PMC: 2449360. DOI: 10.1073/pnas.0803933105. View

20.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J . Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440(7081):237-41. DOI: 10.1038/nature04516. View